Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$11.87 -2.2%	$9.70	$5.01 ▼ $18.70	$83.64M	0.26	113,004 shs	31,699 shs
IRD Opus Genetics	$1.17 +5.9%	$1.06	$0.65 ▼ $1.75	$69.50M	0.01	553,898 shs	1.20 million shs
MNOV MediciNova	$1.29 +1.2%	$1.31	$1.13 ▼ $2.55	$63.76M	0.35	21,352 shs	6,116 shs
PHGE BiomX	$0.51 -30.4%	$0.45	$0.34 ▼ $2.40	$12.44M	1.42	347,190 shs	53,300 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	+5.11%	+6.50%	+30.43%	+59.40%	+51.25%
IRD Opus Genetics	-0.90%	0.00%	-0.90%	+15.79%	+109,999,900.00%
MNOV MediciNova	-2.31%	-6.62%	-0.78%	-8.63%	+12.39%
PHGE BiomX	-16.72%	-14.49%	+13.54%	-14.49%	-74.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRA Atara Biotherapeutics	4.6242 of 5 stars	3.4	4.0	4.7	2.8	3.3	0.6
IRD Opus Genetics	1.8464 of 5 stars	3.5	0.0	0.0	2.6	0.0	0.6
MNOV MediciNova	2.2629 of 5 stars	3.8	3.0	0.0	2.2	0.8	0.0
PHGE BiomX	2.0553 of 5 stars	3.5	0.0	0.0	1.1	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.83	Moderate Buy	$20.00	68.56% Upside
IRD Opus Genetics	3.00	Buy	$7.33	529.47% Upside
MNOV MediciNova	3.50	Strong Buy	$7.00	444.75% Upside
PHGE BiomX	3.00	Buy	$21.00	3,985.60% Upside

Current Analyst Ratings Breakdown

Latest PHGE, ATRA, MNOV, and IRD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2025	MNOV MediciNova	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/27/2025	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/16/2025	MNOV MediciNova	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy ➝ Strong-Buy	$6.00 ➝ $5.00
5/16/2025	PHGE BiomX	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$128.94M	0.65	N/A	N/A	($4.99) per share	-2.38
IRD Opus Genetics	$10.99M	6.32	N/A	N/A	$0.21 per share	5.55
MNOV MediciNova	$1M	N/A	N/A	N/A	$1.07 per share	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	-$85.40M	-$3.72	N/A	N/A	N/A	3.07%	-8.34%	6.61%	N/A
IRD Opus Genetics	-$57.53M	-$2.10	N/A	N/A	N/A	-429.42%	-283.28%	-144.32%	N/A
MNOV MediciNova	-$11.04M	-$0.23	N/A	N/A	N/A	N/A	-20.77%	-19.68%	8/14/2025 (Estimated)
PHGE BiomX	-$28.32M	-$0.85	N/A	N/A	N/A	N/A	-127.82%	-56.50%	N/A

Latest PHGE, ATRA, MNOV, and IRD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	N/A	MNOV MediciNova	-$0.07	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	IRD Opus Genetics	-$0.25	-$0.12	+$0.13	-$0.12	$4.27 million	$2.88 million
8/11/2025	Q2 2025	ATRA Atara Biotherapeutics	-$0.32	$0.19	+$0.51	$0.19	$4.23 million	$17.58 million
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/15/2025	Q1 2025	IRD Opus Genetics	-$0.34	-$0.32	+$0.02	-$0.24	$4.00 million	$4.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A
PHGE BiomX	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	1.70	0.57
IRD Opus Genetics	N/A	1.98	1.98
MNOV MediciNova	N/A	17.66	17.66
PHGE BiomX	0.51	2.84	2.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
IRD Opus Genetics	14.97%
MNOV MediciNova	9.90%
PHGE BiomX	40.57%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	4.00%
IRD Opus Genetics	6.60%
MNOV MediciNova	13.60%
PHGE BiomX	1.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	7.02 million	5.72 million	Optionable
IRD Opus Genetics	14	59.66 million	55.72 million	N/A
MNOV MediciNova	10	N/A	N/A	Optionable
PHGE BiomX	120	26.18 million	44.04 million	Not Optionable

PHGE, ATRA, MNOV, and IRD Headlines

Recent News About These Companies

BiomX Posts Q2 Loss With 14% Cost Drop

August 14 at 2:55 AM | aol.comA

BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript

August 13 at 12:06 PM | seekingalpha.com

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

August 13 at 6:30 AM | globenewswire.com

What to Expect from BiomX's Earnings

August 12 at 3:46 PM | benzinga.com

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

August 6, 2025 | globenewswire.com

BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy

July 14, 2025 | investing.com

BiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis Treatment

July 14, 2025 | msn.com

PHGE | BiomX Inc. Stock Overview (U.S.: NYSE American) | Barron's

July 14, 2025 | barrons.com

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

July 14, 2025 | globenewswire.com

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

July 8, 2025 | globenewswire.com

BiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 Conference

May 21, 2025 | nasdaq.com

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 19, 2025 | globenewswire.com

BiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 15, 2025 | globenewswire.com

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

May 8, 2025 | globenewswire.com

BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

April 18, 2025 | zacks.com

BiomX announces going concern qualification from independent audit

April 1, 2025 | markets.businessinsider.com

BiomX target adjusted to $21 from $2 at H.C. Wainwright

April 1, 2025 | markets.businessinsider.com

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

April 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGE, ATRA, MNOV, and IRD Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$11.86 -0.27 (-2.18%)

As of 03:04 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Opus Genetics NASDAQ:IRD

$1.16 +0.07 (+5.91%)

As of 03:03 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

MediciNova NASDAQ:MNOV

$1.28 +0.02 (+1.18%)

As of 03:01 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

BiomX NYSEMKT:PHGE

$0.51 -0.23 (-30.45%)

As of 03:04 PM Eastern

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time